COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry

Biotech 1 min
July 30, 2020

COVID-19 presents an unprecedented challenge to the global life sciences industry.  Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located.  This update aims to provide guidance on the responses of EU and Asia-Pac regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.

Today we release the latest in our series, focusing on Market Access, please click on the link below to view this tracker:

Other trackers available in this series:

  • COVID-19: Legislation Tracker for Medical Devices, read here
  • COVID-19: Legislation Tracker for Clinical Trials, read here
  • COVID-19: Legislation Tracker for Public Procurement, read here
  • COVID-19: Legislation Tracker for State Use/Compulsory Licensing, read here

Related articles

EMA’s envisaged risk-based and human-centric approach to regulate AI
Bird & Bird’s international life sciences and healthcare team is at the forefront of the legal...
Principle of Automatic Substitution by Biosimilars
Like generic medicines, biological medicines that are very similar to another biological medicine (biosimilars)...